Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AIR645 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution) |
| 2 | PLACEBO_COMPARATOR | Physiologic saline solution |
| Name | Type | Description |
|---|---|---|
| AIR645 | DRUG | AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days. |
| Physiologic saline solution | DRUG | Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days. |
Inclusion Criteria\*: * Good General Health (with or without allergic rhinitis and/or controlled asthma) * Non-smoker for at least 2 years * Normal lung function (DLCO) * Able to provide informed consent and to understand and comply with the requirements of the study Exclusion Criteria\*: * Clini...
AIR645 is an investigational small molecule being developed for the treatment of asthma. It is a respiratory therapeutic that has completed a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
The molecular target of AIR645 has not been disclosed. The drug is a small molecule being studied for its effects in asthma, but its specific mechanism of action is not publicly available from the development data.
AIR645 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research on this investigational asthma treatment.
AIR645 is in Phase 1 clinical development. A Phase 1 study has been completed, but the drug remains investigational and has not received regulatory approval. Further clinical trials would be needed to advance its development.
AIR645 has one completed clinical trial, NCT00658749, titled "A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma." This was a randomized, double-blind, placebo-controlled study with 80 participants in the United States.
No alternative names for AIR645 have been reported. The drug is identified solely by its code name AIR645 in clinical development records.